Stocks Health care APGE
NASDAQ · Health careApogee Therapeutics, Inc. (APGE)
It posted a net loss of $294.4M. In fiscal 2025 capital spending exceeded operating cash flow by $232.6M. At June 30, 2026 it held $105.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
What Apogee Therapeutics, Inc. does
Apogee Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker APGE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$255.8M | -$4.22 | -$232.6M |
| 2024 | n/a | -$182.1M | -$3.30 | -$172.3M |
| 2023 | n/a | -$84M | -$3.36 | -$74.9M |
Latest SEC filings
What Apogee Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026Deregistration 15-12G
- September 8, 2026Activist stake changed SCHEDULE 13D/A
- September 3, 2026Activist stake changed SCHEDULE 13D/A
- September 3, 2026Form POSASR filing POSASR
- September 3, 2026Form S-8 POS filing S-8 POS
- September 3, 2026Form S-8 POS filing S-8 POS
- September 3, 2026Form S-8 POS filing S-8 POS
- September 3, 2026Form S-8 POS filing S-8 POS
- September 3, 2026Form S-8 POS filing S-8 POS
- September 3, 2026Delisting notice 25-NSE
Questions about APGE
What does Apogee Therapeutics, Inc. do?
Apogee Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker APGE.
Is Apogee Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $294.4M.
When did Apogee Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the deregistration from September 14, 2026.
Similar companies
Follow APGE
Get an email when Apogee Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow APGE: get an email when it filesWhere the numbers come from
Financial figures are the values Apogee Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.